<SEC-DOCUMENT>0001062993-24-017785.txt : 20241018
<SEC-HEADER>0001062993-24-017785.hdr.sgml : 20241018
<ACCEPTANCE-DATETIME>20241018215734
ACCESSION NUMBER:		0001062993-24-017785
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20241017
FILED AS OF DATE:		20241018
DATE AS OF CHANGE:		20241018

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Flomenberg Neal
		CENTRAL INDEX KEY:			0002011757
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41002
		FILM NUMBER:		241381831

	MAIL ADDRESS:	
		STREET 1:		C/O TEVOGEN BIO HOLDINGS INC.
		STREET 2:		15 INDEPENDENCE BOULEVARD
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tevogen Bio Holdings Inc.
		CENTRAL INDEX KEY:			0001860871
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981597194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		646-807-8832

	MAIL ADDRESS:	
		STREET 1:		15 INDEPENDENCE BOULEVARD, SUITE 410
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Semper Paratus Acquisition Corp
		DATE OF NAME CHANGE:	20210505
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-10-17</periodOfReport>

    <issuer>
        <issuerCik>0001860871</issuerCik>
        <issuerName>Tevogen Bio Holdings Inc.</issuerName>
        <issuerTradingSymbol>TVGN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002011757</rptOwnerCik>
            <rptOwnerName>Flomenberg Neal</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TEVOGEN BIO HOLDINGS INC.</rptOwnerStreet1>
            <rptOwnerStreet2>15 INDEPENDENCE BLVD, STE 410</rptOwnerStreet2>
            <rptOwnerCity>WARREN</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07059</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-10-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1078600</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.62</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4254302</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement on the transaction date of restricted stock units. Such sales were not made at the discretion of the Reporting Person.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <remarks>Chief Scientific Officer, Global R&amp;D Lead</remarks>

    <ownerSignature>
        <signatureName>/s/ Kirti Desai, Attorney-in-Fact</signatureName>
        <signatureDate>2024-10-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
